Loncastuximab Tesirine

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience.

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience.

Journal: European journal of haematology

Published: February 23, 2026

Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.

Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.

Journal: European journal of haematology

Published: January 28, 2026

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.

Journal: Blood reviews

Published: November 27, 2025

Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.

Journal: Seminars in hematology

Published: September 17, 2025

Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.

Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.

Journal: JCO clinical cancer informatics

Published: July 16, 2025

Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system.

Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system.

Journal: PloS one

Published: July 02, 2025

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.

Journal: Leukemia & lymphoma

Published: June 30, 2025

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Journal: Cancers

Published: June 29, 2025

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Journal: Cancers

Published: June 26, 2025

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.

Journal: British journal of haematology

Published: June 17, 2025

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.

Journal: Future oncology (London, England)

Published: May 30, 2025

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study.

How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study.

Journal: Future oncology (London, England)

Published: May 29, 2025

Showing 1-12 of 91

Last Updated: 04/28/2026